Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist

Tetrahedron

Volumn 64, Issue 48, 2008, Pages 10802-10809

  Kim, Min ah ^a   Yun, Hoseop ^b   Kwak, HyunJung ^b   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

^b Ajou University   (South Korea)

Author keywords

Anti obesity; Evans asymmetric reaction; Hydride reduction; Taranabant

Indexed keywords

ALPHA BROMOKETONE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; KETONE DERIVATIVE; TARANABANT; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; DRUG BINDING; DRUG DESIGN; DRUG SYNTHESIS; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOCHEMISTRY; SUBSTITUTION REACTION;

EID: 53449097224     PISSN: 00404020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tet.2008.09.057     Document Type: Article

References (27)

1. Klein S., Wadden T., and Sugerman H.J. Gastroenterology 123 (2002) 882-932
2. Patel P.N., and Pathak R. Am. J. Health Syst. Pharm. 64 (2007) 481-489
3. Bray G.A. J. Med. Chem. 49 (2006) 4001-4007
4. Haslam D.W., and James W.P.T. Lancet 366 (2005) 1197-1209
5. Fry J., and Finley W. Proc. Nutr. Soc. 64 (2005) 359-362
6. Report of a WHO Consultation on Obesity: Obesity-Preventing and Managing a Global Epidemic (1997), World Health Organization, Geneva
7. Antel J., Gregory P.C., and Nordheim U. J. Med. Chem. 49 (2006) 4008-4016
8. Aronne L.J., and Thornton-Jones Z.D. Clin. Pharmacol. Ther. 81 (2007) 748-752
9. Padwal R.S., and Majumdar S.R. Lancet 369 (2007) 71-77
10. Bishop M.J. J. Med. Chem. 49 (2006) 3999-4000
11. Li Z., Maglione M., Tu W., Mojica W., Aterburn D., Shugarman L., Hilton L., Suttorp M., Solomon V., Shekelee P.G., and Morton S.C. Ann. Intern. Med. 142 (2005) 532-546
12. Kang S.Y., Lee S.-H., Seo H.J., Jung M.E., Ahn K., Kim J., and Lee J. Bioorg. Med. Chem. Lett. 18 (2008) 2385-2389
13. Kim M.-a., Kim J.Y., Song K.-S., Kim J., and Lee J. Tetrahedron 63 (2007) 12845-12852
14. Lin L.S., Ha S., Ball R.G., Tsou N.N., Castonguay L.A., Doss G.A., Fong T.M., Shen C.-P., Xiao J.C., Goulet M.T., and Hagmann W.K. J. Med. Chem. 51 (2008) 2108-2114
15. Myers A.G., Yang B.H., Chen H., and Gleason J.L. J. Am. Chem. Soc. 116 (1994) 9361-9362
16. Myers A.G., Yang B.H., Chen H., McKinstry L., Kopecky D.J., and Gleason J.L. J. Am. Chem. Soc. 119 (1997) 6496-6511
17. Reider P.J. Chimia 51 (1997) 306-308
18. Shimizu S., and Ogata M. J. Org. Chem. 51 (1986) 3897-3900
19. Ogata M., Matsumoto H., Takahashi K., Shimizu S., Kida S., Murabayashi A., Shiro M., and Tawara K. J. Med. Chem. 30 (1987) 1054-1068
20. Lin L.S., Lanza T.J., Jewell J.P., Liu P., Shah S.K., Qi H., Tong X., Wang J., Xu S.S., Fong T.M., Shen C.-P., Lao J., Xiao J.C., Shearman L.P., Stribling D.S., Rosko K., Strack A., Marsh D.J., Feng Y., Kumar S., Samuel K., Yin W., Van der Ploeg L.H.T., Goulet M.T., and Hagmann W.K. J. Med. Chem. 49 (2006) 7584-7587
21. Wong A., Welch C.J., Kuethe J.T., Vazquez E., Shaimi M., Henderson D., Davies I.W., and Hughes D.L. Org. Biomol. Chem. 2 (2004) 168-174
22. Coburn, C.; Espeseth, A. S.; Stachel, S. J.; Olsen, D. B.; Hazuda, D.; Holloway, M. K. WO2005/097767, 2005.
23. Yokokawa F., Asano T., and Shioiri T. Org. Lett. 2 (2000) 4169-4172
24. Devane W.A., Dysarz III F.A., Johnson M.R., Melvin L.S., and Howlett A.C. Mol. Pharmacol. 34 (1998) 605-613
25. 50=4.50 nM via in-house assay.
26. Triazole is small and constitutes three nitrogens in the ring. Thus, by substituting H into a triazole, hydrophilicity of a molecule increases. Concurrent alteration of physicochemical properties including solubility was observed.
27. Currently, Merck's taranabant is in Phase 3 clinical trial for the treatment of obesity in USA. Taranabant is not toxic per se, but people speculate that it might have potential problem to cause depression or anxiety in human beings when it is used in medium to high dose.